美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Russell Investments Core Plus Bond ETF

24.25

-0.0187-0.08%

盤後：24.270.0187+0.08%16:04 EDT

成交量：209

成交額：5,081

市值：5,686.39萬

市盈率：- -

高：24.25

開：24.27

低：24.25

收：24.27

52周最高：25.19

52周最低：24.25

股本：234.50萬

流通股本：234.50萬

量比：4.69

換手率：0.01%

股息：0.23

股息率：0.93%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

480家藥企，最新營收、淨利潤來了

港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條

【券商聚焦】國投證券維持康諾亞-B（02162）買入評級指核心產品放量及BD兑現

信達生物：對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.249,"timestamp":1789156800000,"preClose":24.2677,"halted":0,"volume":209,"hourTrading":{"tag":"盘后","latestPrice":24.2677,"preClose":24.249,"latestTime":"16:04 EDT","volume":2,"amount":48.498,"timestamp":1789157049214,"change":0.0187,"changeRate":0.000771,"amplitude":0},"delay":0,"changeRate":-0.0007705715828035868,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"休市中","change":-0.0187,"latestTime":"09-11 16:00:00 EDT","open":24.2677,"high":24.249,"low":24.249,"amount":5081,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":24.2677,"nav":24.335265,"aum":57066195.36,"dividendRate":0.009308,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.2677,"preClose":24.249,"latestTime":"16:04 EDT","volume":2,"amount":48.498,"timestamp":1789157049214,"change":0.0187,"changeRate":0.000771,"amplitude":0},"volumeRatio":4.68609760401399},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2345000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.68609760401399,"shares":2345000,"dividePrice":0.2257,"high":24.249,"amplitude":0,"preClose":24.2677,"low":24.249,"week52Low":24.249,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.249,"eps":0,"divideRate":0.009308,"volume":209,"delay":0,"ttmEps":0,"open":24.2677,"prevYearClose":25.08,"prevWeekClose":24.635,"prevMonthClose":24.7551,"prevQuarterClose":25.19,"fiveDayClose":24.635,"twentyDayClose":24.825},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-09-02","symbol":"BD","amount":0.104028,"announcedDate":"2026-09-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-02","defaultRemindTime":1788355800000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-04","payableDate":"2026-09-02","currency":"USD","dateTimestamp":1788321600000,"payDate":"2026-09-04"},{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"},{"executeDate":"2026-09-02","recordDate":"2026-09-02","paymentDate":"2026-09-04","value":0.104028,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665320971","title":"480家藥企，最新營收、淨利潤來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320971","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:39","pubTimestamp":1788867540,"startTime":"0","endTime":"0","summary":"2026年上半年，480家药企合计实现营收7,369.82亿元，同比增长+2.48%；实现归母净利润988.94亿元，同比增长+12.35%。荣昌生物营收58.53亿元，归母净利润46.62亿元，主要受海外授权合作首付款及里程碑款驱动，是板块利润暴增的最大来源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircmeq9268445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上，近日，乐普生物发布截至2026年6月30日止六个月业绩，收入5.22亿元，同比增长12.1%；公司拥有人应占利润2739.3万元，同比下降34.4%；每股基本盈利0.02元。国联民生证券发布研报称，乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent，实现研发能力变现。在商业模式上，公司已成功构建并验证了国内商业化能力，同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动，持续优化收入结构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","VXUS","KCAI","BD","BK4588","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】國投證券維持康諾亞-B（02162）買入評級 指核心產品放量及BD兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662623760?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，康诺亚-B 2026年中期实现营业收入6.17亿元人民币，同比增长24%；实现净利润12.18亿元人民币，上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日，公司现金及金融资产合计32.42亿元人民币，较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展，维持“买入-A”评级，根据DCF模型给予6个月目标价90.37港元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BD","161027","02162","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662994764","title":"信達生物：對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2662994764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662994764?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 11:58","pubTimestamp":1787716704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BD\",params:#limit:6,delay:false,,,undefined,":[]}}